Pre-emptive treatment of acute GVHD: A randomized multicenter trial of rabbit anti-thymocyte globulin, given on day7 after alternative donor transplants

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 385-391

  Bacigalupo, A ^a   Lamparelli, T ^a   Milone, G ^a   Sormani, M P ^a   Ciceri, F ^a   Peccatori, J ^a   Locasciulli, A ^a   Majolino, I ^a   Di Bartolomeo, P ^a   Mazza, F ^a   Sacchi, N ^a   Pollicheni, S ^a   Pinto, V ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GAMMA GLUTAMYLTRANSFERASE; METHOTREXATE; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INFECTION; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL RATE; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; CAUSE OF DEATH; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIVARIATE ANALYSIS; RABBITS; RECURRENCE; RISK;

EID: 76749165710     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.151     Document Type: Article

References (28)

1. Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877-3886.
2. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3-10.
3. Teshima T, Ferrara JL. Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol 2002; 39: 15-22.
4. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid resistant acute graft versus host disease. Biol Blood Marrow Transplant 2004; 10: 655-668.
5. Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving antithymocyte globulin. Blood 2006; 107: 4177-4181.
6. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98: 2052-2058.
7. Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graftversus- host disease. Biol Blood Marrow Transplant 2005; 11: 680-687.
8. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer 2005; 49: 212-212
9. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH et al. Infliximab use in patients with severe graftversus- host disease and other emerging risk factors of non- Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients. A cohort study. Blood 2003; 102: 2768-2776.
10. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. Tumor necrosis factor alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
11. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470-2475.
12. Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplant 1999; 24: 653-659.
13. Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM et al. Pre-emptive therapy of acute graft versus host disease: a pilot study with anti-thymocyte globulin (ATG). Bone Marrow Transplant 2001; 28: 1093-1096.
14. Sormani MP, Oneto R, Bruno B, Fiorone M, Lamparelli T, Gualandi F et al. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 2003; 32: 205-211.
15. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
16. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graftversus- host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
17. Remberger M, Storer B, Ringden O, Anasetti C. Association between pre-transplant thymoglobuline and reduced non relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391-397.
18. Zander AR, Zabelina T, Kroger N, Renges H, Kruger W, Loliger C et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999; 23: 889-893.
19. Duggan P, Booth K, Chaudhry A, Stewart D, Ruether JD, Gluck S, et al., Alberta Blood and Bone Marrow Transplant Program. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002; 30: 681-686.
20. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12: 573-584.
21. Duggan P, Booth K, Chaudhry A, Stewart D, Ruether JD, Gluck S, et al., Alberta Blood and Bone Marrow Transplant Program. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002; 30: 681-686.
22. Holler E, Ledderose G, Knabe H, Muth A, Gunther C, Wilmanns W et al. ATG serotherapy during pre-transplant conditioning in unrelated donor BMT: dose-dependent modulation of GVHD. Bone Marrow Transplant 1998; 21(Suppl 1): 105a.
23. Bacigalupo A. Anti-lymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005; 35: 225-231.
24. Ramsay NKC, Kersey JH, Robinson LL, McGlave PB, Woods WG, Krivit W et al. A randomized study of the prevention of acute graft versus host disease. N Engl J Med 1982; 306: 392-397.
25. Sormani MP, Ibatici A, Dominietto A, Van Lint MT, Gualandi F, Lamparelli T et al. Graft-versus-host diseased prophylaxis with antithymocyte globulin (ATG): Which is more important, dose or timing? Bone Marrow Transplant 2007; 39(Suppl 1): S25.
26. Remberger M, Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005; 90: 931-938.
27. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al., Gruppo Italiano Trapianti Midollo Osseo (GITMO). Thymoglobulin prevents chronic graftversus- host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560-565.
28. Dominietto A, Tedone E, Soracco M, Ibatici A, Raiola AM, van Lint MT et al. Reduced relapse related death in alternative donor transplants with EBV/CMV reactivation. Bone Marrow Transplant 2008; 41(Suppl 1): S266.